Seagen Stock Forecast, Price & News

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last twelve months. There are currently 6 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Seagen stock.
View analyst ratings for Seagen or view top-rated stocks.

Wall Street analysts have given Seagen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Seagen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Seagen saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,670,000 shares, an increase of 43.9% from the March 15th total of 2,550,000 shares. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is presently 3.2 days.
View Seagen's Short Interest.

Seagen is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Seagen.

Seagen Inc. (NASDAQ:SGEN) announced its earnings results on Thursday, April, 29th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.59) by $0.08. Seagen had a net margin of 25.34% and a trailing twelve-month return on equity of 20.46%.
View Seagen's earnings history.

Seagen's stock was trading at $104.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SGEN shares have increased by 29.3% and is now trading at $135.08.
View which stocks have been most impacted by COVID-19.

16 equities research analysts have issued 12 month price objectives for Seagen's shares. Their forecasts range from $145.00 to $254.00. On average, they anticipate Seagen's share price to reach $188.92 in the next year. This suggests a possible upside of 39.9% from the stock's current price.
View analysts' price targets for Seagen or view top-rated stocks among Wall Street analysts.

107 employees have rated Seagen CEO Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among Seagen's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Seagen include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of SGEN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), salesforce.com (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Seagen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Manning & Napier Group LLC (0.50%), Sumitomo Mitsui Trust Holdings Inc. (0.24%), Victory Capital Management Inc. (0.08%), DekaBank Deutsche Girozentrale (0.06%), Robeco Institutional Asset Management B.V. (0.05%) and State of New Jersey Common Pension Fund D (0.04%). Company insiders that own Seagen stock include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Lip Bu Tan, Marc E Lippman, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson and Vaughn B Himes.
View institutional ownership trends for Seagen.

SGEN stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Robeco Institutional Asset Management B.V., Los Angeles Capital Management LLC, Commerce Bank, M&T Bank Corp, Natixis Advisors L.P., KBC Group NV, and Exchange Traded Concepts LLC. Company insiders that have sold Seagen company stock in the last year include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Roger D Dansey, Todd E Simpson, and Vaughn B Himes.
View insider buying and selling activity for Seagen or view top insider-selling stocks.

SGEN stock was purchased by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Strs Ohio, DekaBank Deutsche Girozentrale, NN Investment Partners Holdings N.V., Envestnet Asset Management Inc., Victory Capital Management Inc., Nisa Investment Advisors LLC, and DnB Asset Management AS.
View insider buying and selling activity for Seagen or or view top insider-buying stocks.

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SGEN stock can currently be purchased for approximately $135.08.

Seagen has a market capitalization of $24.51 billion and generates $916.71 million in revenue each year. The biotechnology company earns $-158,650,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.

Seagen employs 2,092 workers across the globe.

Seagen was founded in 1998.

The official website for Seagen is www.seattlegenetics.com.

Seagen is headquartered at 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021.

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]